Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.

Rhea-AI Summary

Co-Diagnostics, Inc. (CODX) announced its participation in the 16th Annual Next Generation Dx Summit in Washington, D.C. from August 19-21, 2024. The company will sponsor, present, and host a booth at this event, which focuses on diagnostic advancement and technology innovation.

CEO Dwight Egan will present on the company's upcoming PCR platform, currently under FDA review, in a luncheon presentation titled "Co-Dx PCR Platform: The Future of Accessible Diagnostics" on August 19 at 12:15 PM ET.

Attendees can visit Booth #26 to learn about the Co-Dx PCR testing platform and the Co-Dx Logix Smart® suite of clinical laboratory solutions, including Research Use Only (RUO) tests for mpox virus. The company's mpox test was featured in a study published in the Oxford Academic journal Open Forum Infectious Diseases in December 2023.

SALT LAKE CITY, Aug. 15, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 16^th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 19-21, 2024.

Cambridge Healthtech Institute's Next Generation Dx Summit is described as the nexus for international thought leaders to discuss diagnostic advancement and technology innovation, and offers a valuable window into how point-of-care, decentralized testing, infectious disease, liquid biopsy and companion diagnostics are changing the standard of care.

On Monday, August 19, at 12:15 PM ET, Company CEO Dwight Egan will be presenting on the Company's forthcoming PCR platform, which is currently under FDA review and is not currently for sale, in a luncheon presentation titled "Co-Dx PCR Platform: The Future of Accessible Diagnostics."

Attendees are invited to visit the Company at Booth #26 to learn more about the upcoming Co-Dx PCR testing platform as well as the Co-Dx Logix Smart® suite of clinical laboratory solutions. These solutions include Research Use Only (RUO) tests for mpox** virus, one of which was included in a study published in the Oxford Academic journal Open Forum Infectious Diseases in December, 2023. Yesterday, the World Health Organization Director-General declared mpox a public health emergency of international concern (PHEIC).

To learn more about the summit, including in-person and virtual registration details, please visit https://www.nextgenerationdx.com.

*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA and are not available for sale.

**The Co-Dx Logix Smart® Mpox and Co-Dx Logix Smart® Mpox 2-Gene tests are for Research Use Only. Not for use in diagnostic procedures.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-16th-next-generation-dx-summit-in-washington-dc-302223138.html

SOURCE Co-Diagnostics

FAQ

When and where is Co-Diagnostics (CODX) presenting at the Next Generation Dx Summit?

Co-Diagnostics (CODX) is presenting at the 16th Annual Next Generation Dx Summit in Washington, D.C. on August 19, 2024, at 12:15 PM ET.

What will Co-Diagnostics (CODX) showcase at the Next Generation Dx Summit?

Co-Diagnostics (CODX) will showcase its upcoming PCR platform, which is currently under FDA review, and the Co-Dx Logix Smart® suite of clinical laboratory solutions, including Research Use Only (RUO) tests for mpox virus.

Where can attendees find Co-Diagnostics (CODX) at the Next Generation Dx Summit?

Attendees can visit Co-Diagnostics (CODX) at Booth #26 during the Next Generation Dx Summit.

What is the title of Co-Diagnostics (CODX) CEO's presentation at the summit?

Co-Diagnostics (CODX) CEO Dwight Egan will present a luncheon presentation titled "Co-Dx PCR Platform: The Future of Accessible Diagnostics."

Has Co-Diagnostics (CODX) conducted any research on mpox virus tests?

Yes, Co-Diagnostics (CODX) has developed Research Use Only (RUO) tests for mpox virus, one of which was included in a study published in the Oxford Academic journal Open Forum Infectious Diseases in December 2023.